PRTA Prothena Corp Public Ltd Co

Price (delayed)

$74.955

Market cap

$3.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.82

Enterprise value

$2.99B

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
The net income has grown by 43% from the previous quarter and by 23% YoY
The company's EPS rose by 41% QoQ and by 20% YoY
The quick ratio has dropped by 58% year-on-year and by 48% since the previous quarter

Key stats

What are the main financial stats of PRTA
Market
Shares outstanding
45.05M
Market cap
$3.38B
Enterprise value
$2.99B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.49
Price to sales (P/S)
54.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.23
Earnings
Revenue
$60.75M
EBIT
-$65.33M
EBITDA
-$58.42M
Free cash flow
-$35.72M
Per share
EPS
-$1.82
Free cash flow per share
-$0.81
Book value per share
$6.52
Revenue per share
$1.37
TBVPS
$9.84
Balance sheet
Total assets
$436.38M
Total liabilities
$148.17M
Debt
$15.15M
Equity
$288.21M
Working capital
$356.57M
Liquidity
Debt to equity
0.05
Current ratio
7.74
Quick ratio
7.58
Net debt/EBITDA
6.61
Margins
EBITDA margin
-96.2%
Gross margin
100%
Net margin
-115.9%
Operating margin
-107.5%
Efficiency
Return on assets
-18.7%
Return on equity
-30.7%
Return on invested capital
-285.8%
Return on capital employed
-17%
Return on sales
-107.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTA stock price

How has the Prothena stock price performed over time
Intraday
-3.15%
1 week
-0.1%
1 month
10.02%
1 year
649.55%
YTD
524.1%
QTD
45.8%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$60.75M
Gross profit
$60.75M
Operating income
-$65.31M
Net income
-$70.39M
Gross margin
100%
Net margin
-115.9%
Prothena's net margin has soared by 99% from the previous quarter and by 99% YoY
The operating margin has soared by 99% since the previous quarter and by 99% year-on-year
Prothena's operating income has increased by 46% QoQ and by 32% YoY
The net income has grown by 43% from the previous quarter and by 23% YoY

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
11.49
P/S
54.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.23
The company's EPS rose by 41% QoQ and by 20% YoY
PRTA's price to book (P/B) is 182% higher than its last 4 quarters average of 4.2
The company's equity rose by 23% YoY and by 23% QoQ
PRTA's price to sales (P/S) is 91% lower than its 5-year quarterly average of 634.1 and 90% lower than its last 4 quarters average of 572.9

Efficiency

How efficient is Prothena business performance
The company's return on sales has surged by 99% QoQ and by 99% YoY
The ROIC has plunged by 57% YoY but it has grown by 16% from the previous quarter
The ROE has increased by 47% from the previous quarter and by 11% YoY
Prothena's return on assets has increased by 46% QoQ and by 15% YoY

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
The total assets is 195% more than the total liabilities
The quick ratio has dropped by 58% year-on-year and by 48% since the previous quarter
PRTA's current ratio has dropped by 58% year-on-year and by 48% since the previous quarter
Prothena's debt is 95% less than its equity
Prothena's debt to equity has decreased by 44% YoY and by 29% QoQ
Prothena's debt has decreased by 26% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.